Chronic Heart Failure - Current and Future Players

  • June 2013
  • -
  • Global Data
  • -
  • 38 pages

Chronic Heart Failure - Current and Future Players



Summary



GlobalData has released its pharma report, “Chronic Heart Failure - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Chronic heart failure (CHF) Market. The report identifies and analyses the key companies shaping and driving the global CHF market. The report provides insight into the competitive CHF landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.



Scope


- Investigation of current and future market competition for CHF
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of CHF sector through market impact analysis, future market scenario and company analysis



Reasons to buy


- Gain a high level view of the trends shaping and driving CHF Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global CHF market landscape? Identify, understand and capitalize

Table Of Contents

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Related Reports 7
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers - Global Issues 12
4 Current and Future Players 16
4.1 Overview 16
4.2 Trends in Corporate Strategy 17
4.3 Company Profiles 18
4.3.1 Novartis 18
5 Appendix 22
5.1 Bibliography 22
5.2 Abbreviations 22
5.3 Methodology 23
5.4 Forecasting Methodology 23
5.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 23
5.4.2 Diagnosed CHF Population 24
5.4.3 Drug-Treated CHF Population 25
5.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 25
5.4.5 Treatment of HF-REF versus HF-PEF 25
5.4.6 Drugs Included in Each Therapeutic Class 26
5.4.7 Launch and Patent Expiry Dates 26
5.4.8 General Pricing Assumptions 27
5.4.9 Drugs Assumptions 28
5.4.10 Generic Erosion 33
5.4.11 Pricing of Pipeline Agents 33
5.5 Physicians and Specialists Included in this Study 34
5.6 Survey of Prescribing Physicians 35
5.7 About the Authors 36
5.7.1 Author 36
5.7.2 Global Head of Healthcare 36
5.8 About GlobalData 37
5.9 Disclaimer 37



List of Tables

Table 1: Global Sales Forecasts ($m) for CHF, 2012-2022 10
Table 2: Global CHF Market - Drivers and Barriers, 2012-2022 12
Table 3: Key Companies in the CHF Market, 2012 17
Table 4: Novartis’ CHF Portfolio Assessment, 2012 20
Table 5: Novartis SWOT Analysis, 2012 21
Table 6: Key Launch or Approval Dates 26
Table 7: Key Patent Expiries 26
Table 8: Physicians Surveyed, By Country 35



List of Figures

Figure 1: Global Sales for CHF ($bn) by Region, 2012-2022 11



Companies Mentioned

Novartis

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.